Sanpower completes Dendreon acquisition

Sanpower Group Co. Ltd. (Nanjing, China) said it completed the purchase of Dendreon Pharmaceuticals Inc. from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) for $819.9 million in cash.

In February 2015, Valeant acquired bankrupt Dendreon's assets, including global rights to prostate cancer vaccine Provenge sipuleucel-T, for $415 million net of cash received. Approved by FDA in 2010, Provenge consists of autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and an immunostimulatory cytokine (see BioCentury Extra, Jan. 10)...